Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests deucravacitinib for skin patches in teens with psoriasis

Tests deucravacitinib against placebo in teens with moderate to severe plaque psoriasis.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Key facts

Where
Barranquilla, Bogota, and Medellín, ColombiaSee the 4 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adolescents aged 12 to 17 years with moderate to severe plaque psoriasis that has been stable for at least 6 months.

Age
12 to 17 years (12 years to less than 18 years).
Sex
All sexes can join.
Disease stage
Stable plaque psoriasis for 6 months or more, moderate to severe: PASI 12 or higher, sPGA 3 or higher, and at least 10% of body surface involved.
Earlier treatment
People who have had deucravacitinib before cannot join. Live vaccines or BCG within 60 days before Day 1 are not allowed.

Main reasons for not taking part

  • Weight under 30.0 kg (66 lb)
  • Psoriasis types other than plaque psoriasis, such as guttate, inverse, pustular or erythrodermic
  • Serious or untreated bacterial, fungal or viral infection, or chronic bacterial infection
  • Active tuberculosis, hepatitis B, hepatitis C or HIV infection-related exclusions
  • Cancer or history of cancer within the previous 5 years

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 17 years old?

Source: NCT06979453, who can take part

Where in Colombia

  • Barranquilla, AtlánticoHospital not named in the registryContact: Site 0167Not yet recruiting
  • Bogota, CundinamarcaHospital not named in the registryContact: Site 0125Not yet recruiting
  • Medellín, AntioquiaHospital not named in the registryContact: Site 0124Not yet recruiting
  • Medellín, AntioquiaHospital not named in the registryContact: Site 0225Not yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb
Trial code
NCT06979453EU 2023-506296-97-00
Record updated
27 October 2026
Original description
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasisRead full original descriptionShow less

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Inclusion: Participants must have stable plaque psoriasis for 6 months or more prior to Screening; Participants must have moderate to severe psoriasis defined by:; Psoriasis Area and Severity Index (PASI) ≥ 12, at screening visit and Day 1; Static Physician's Global Assessment (sPGA) ≥ 3, at screening visit and Day 1; Body Surface Area (BSA) ≥ 10% involvement, at screening visit and Day 1; A female (as assigned at birth) participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:; Is not an individual of childbearing potential (IOCBP); Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year) during the study intervention period and for at least 3 days after discontinuation of the study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.

Exclusion: Participants must not have a history of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous (IV) antimicrobial treatment within 60 days prior to Day 1; Participants must not have any untreated bacterial infection within 60 days prior to Day 1; Participants must not have received live vaccines or BCG within 60 days prior to Day 1 or plans to receive a live vaccine during the study, or within 60 days after completing study intervention; Participants must not have had any prior exposure to deucravacitinib; Participants must not have received any medication that is specifically prohibited; Participants must not have non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) or any skin condition other than plaque psoriasis that could interfere with assessments of treatment effect at Screening or Day 1; Participants must not have any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis); Participants must not have herpes simplex/zoster, active tuberculosis (TB), hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV) infection-related exclusions; Participants must not have any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection/infectious illness) that, in the investigator's judgment or after consultation with the Sponsor's Medical Monitor, will substantially increase the risk to the participant if he or she participates in the study; Participants must not have cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years; Participants must not have a laboratory finding that is exclusionary; Participants must not weigh < 30.0 kg at Screening and Day 1; Other protocol-defined Inclusion/Exclusion criteria apply.

ClinicalTrials.gov NCT06979453 · EU CTIS 2023-506296-97-00